Spunout of Duke, Precision BioSciences, Inc. is a clinical stage biotechnology company developing and commercializing therapeutics and services based on genomic molecular biology and dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Companys pipeline consists of multiple ex vivo off-the-shelf CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. The firm offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock. Precisions proprietary ARCUS genome editing technology essentailly enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. The firm went public (NASDAQ: DTIL) in May 2019
